ClinicalTrials.gg
TerminatedNCT06485687Updated Nov 17, 2026

Low Intensity Focused Ultrasound for Binge Eating Disorder

An interventional study of LIFU Neuromodulation in Binge-Eating Disorder, sponsored by Ali Rezai. Terminated at 1 site in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Ali Rezai · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
poor accrual,
Updated Nov 17, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Binge-Eating Disorder with a site in United States — 19 open to participants now, 26 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Enrollment
110th of 112
4 · median 67
Started
2024
with 7 others
No phase
64 of 122
14 open now
Registered
102nd of 122
by date

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 110th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2024, is one of 64 with no phase, and was the 102nd registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 50 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

19 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 22 (67%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with Binge Eating Disorder (BED)

Read the detailed description

The primary objective is to evaluate the safety, feasibility and tolerability of LIFU as an adjunct neuromodulatory treatment for BED

03

Conditions studied

  • Binge-Eating Disorder

Browse trials for

04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and non-pregnant females, 22 - 65 years of age.
  • Participant meets criteria for moderate to extreme BED.
  • Weight ≤450lb to accommodate in MRI.
  • Shoulder width of ≤65 inches to accommodate in MRI.
  • The neuromodulation targets are visible on MRI for target selection.
  • Participant is able and willing to give .

Exclusion criteria

Exclusion Criteria:

  • Unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent make-up or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small spaces (have claustrophobia).
  • Participants with more than 30% of the skull area traversed by the sonication pathway are covered by scars, scalp disorders (e.g., eczema), atrophy of the scalp, or implanted objects in the skull or the brain.
  • Participants with known untreated or unstable cardiac status or hypertension
  • Evidence of substance (alcohol or other drug) use disorder during the previous 12 months (assessed via SCID-5).
  • Past or present diagnosis of schizophrenia, psychotic disorder or bipolar disorder (assessed via SCID-5)
  • Participant who is currently participating in another clinical investigation with an active treatment arm.
  • Use of any medications that, in the opinion of the Investigator, may put the participant at higher risk for AEs, or impair the participant's ability to perform complete study procedures.
  • Participant is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator.
  • Participant is pregnant/lactating or planning to be pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    LIFU Neuromodulation

    Device: LIFU Neuromodulation

Interventions

  • DeviceLIFU Neuromodulation

    Subjects will undergo a single LIFU of the target brain region

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events

    All adverse events that are related to LIFU procedure will be assessed

    Time frame: [baseline and day 7 and 90 after study procedure

Secondary outcomes

  1. Effect of LIFU on Food craving

    Visual Analog scale and food diary

    Time frame: Day 1, Day 7, Day 30, Day 60, Day 90; comparisons will be made relative to baseline, pre-LIFU.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2024 to primary completion in Sep 2026, 22 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 3, 2024
StartActual
Oct 31, 2024
Primary completionActual
Sep 30, 2026was Dec 2026
CompletionActual
Sep 30, 2026was Dec 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated poor accrual,
changed Nov 17, 2026
Primary completion
Dec 31, 2026→Sep 30, 2026 (actual)
Nov 17, 2026
Study completion
Dec 31, 2027→Sep 30, 2026 (actual)
Nov 17, 2026
Enrollment
15 (estimated)→4 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Active, not recruiting→Terminated
    Why stopped poor accrual,
    Primary completion Dec 31, 2026→Sep 30, 2026 (now actual)
    Study completion Dec 31, 2027→Sep 30, 2026 (now actual)
    Enrollment 15 (estimated)→4 (actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06485687
Lead sponsor
Ali Rezai
Responsible party
Ali Rezai (Director RNI, West Virginia University) — Sponsor-investigator
First posted
Jul 3, 2024
Start date
Oct 31, 2024
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 17, 2026

Study contacts

Ali Rezai
principal investigator · WVU Rockefeller Neuroscience Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion